Trials / Completed
CompletedNCT02722408
Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)
A Phase 2 Open-Label, Dose-Finding Study to Assess the Efficacy, Safety, and Tolerability of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid Lowering Therapy (COBALT-1)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- NeuroBo Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to assess the efficacy, safety, and tolerability of multiple doses of Gemcabene in patients with HoFH on stable, lipid-lowering therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gemcabene | 300 mg tablet orally once daily for four weeks followed by 600 mg tablet orally once daily for four weeks followed by 900 mg tablet orally once daily for four weeks. |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2017-04-01
- Completion
- 2017-07-01
- First posted
- 2016-03-30
- Last updated
- 2020-06-25
- Results posted
- 2020-06-25
Locations
7 sites across 3 countries: United States, Canada, Israel
Source: ClinicalTrials.gov record NCT02722408. Inclusion in this directory is not an endorsement.